ZA988750B - Tetrazole-containing rapamycin analogs with shortened half-lives - Google Patents

Tetrazole-containing rapamycin analogs with shortened half-lives

Info

Publication number
ZA988750B
ZA988750B ZA988750A ZA988750A ZA988750B ZA 988750 B ZA988750 B ZA 988750B ZA 988750 A ZA988750 A ZA 988750A ZA 988750 A ZA988750 A ZA 988750A ZA 988750 B ZA988750 B ZA 988750B
Authority
ZA
South Africa
Prior art keywords
tetrazole
lives
rapamycin analogs
containing rapamycin
shortened half
Prior art date
Application number
ZA988750A
Other languages
English (en)
Inventor
Karl W Mollison
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25470968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA988750(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ZA988750B publication Critical patent/ZA988750B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA988750A 1997-09-26 1998-09-23 Tetrazole-containing rapamycin analogs with shortened half-lives ZA988750B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93814497A 1997-09-26 1997-09-26

Publications (1)

Publication Number Publication Date
ZA988750B true ZA988750B (en) 1999-04-01

Family

ID=25470968

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988750A ZA988750B (en) 1997-09-26 1998-09-23 Tetrazole-containing rapamycin analogs with shortened half-lives

Country Status (28)

Country Link
EP (1) EP1015459B9 (ko)
JP (1) JP3790424B2 (ko)
KR (3) KR100700319B1 (ko)
CN (1) CN1161360C (ko)
AR (1) AR015940A1 (ko)
AT (1) ATE297398T1 (ko)
AU (1) AU745576B2 (ko)
BG (1) BG64955B1 (ko)
BR (1) BR9812305A (ko)
CA (1) CA2303934C (ko)
CO (1) CO5070656A1 (ko)
CZ (1) CZ299365B6 (ko)
DE (1) DE69830502T2 (ko)
DK (1) DK1015459T3 (ko)
ES (1) ES2244087T3 (ko)
HK (1) HK1030771A1 (ko)
HU (1) HU228368B1 (ko)
IL (2) IL134607A0 (ko)
NO (1) NO325813B1 (ko)
NZ (2) NZ514778A (ko)
PL (1) PL191212B1 (ko)
PT (1) PT1015459E (ko)
SI (1) SI1015459T1 (ko)
SK (1) SK285408B6 (ko)
TR (1) TR200000778T2 (ko)
TW (1) TW557297B (ko)
WO (1) WO1999015530A1 (ko)
ZA (1) ZA988750B (ko)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1482975B1 (en) * 2002-01-29 2006-12-13 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Prevention of tissue adhesion
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
DK1505959T3 (da) 2002-05-16 2009-02-23 Novartis Ag Anvendelse af EDG-receptorbindingsmidler ved cancer
CN100351244C (zh) 2002-05-27 2007-11-28 诺瓦提斯公司 双芳族链烷醇
EP1536850B1 (en) * 2002-09-06 2016-08-10 Abbott Laboratories Medical device having hydration inhibitor
BR0314760A (pt) 2002-09-24 2005-07-26 Novartis Ag Compostos orgânicos
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CA2524048C (en) 2003-05-19 2013-06-25 Irm Llc Immunosuppressant compounds and compositions
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006050461A1 (en) 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
KR101406415B1 (ko) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
EP1912675B1 (en) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC B-cell reduction using cd37-specific and cd20-specific binding molecules
CA2621083C (en) 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
PL2019657T3 (pl) 2006-04-26 2015-10-30 Micell Technologies Inc Powłoki zawierające wiele leków
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
NZ574654A (en) * 2006-07-25 2012-03-30 Abbott Lab Crystalline forms of rapamycin analogs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
JP5603598B2 (ja) 2007-01-08 2014-10-08 ミセル テクノロジーズ、インコーポレイテッド 生物分解層を有するステント
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
AU2009251504B2 (en) 2008-04-17 2013-09-05 Micell Technologies, Inc. Stents having bioabsorbable layers
KR20160131126A (ko) 2008-06-20 2016-11-15 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
WO2011009096A1 (en) 2009-07-16 2011-01-20 Micell Technologies, Inc. Drug delivery medical device
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
EP2379498B1 (en) 2008-12-18 2015-01-21 Novartis AG Polymorphic form of 1-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl) -azetidine-3-carboxylic acid
JP2012512885A (ja) 2008-12-18 2012-06-07 ノバルティス アーゲー 新規な塩
AU2009335924B2 (en) 2008-12-18 2012-11-08 Novartis Ag Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
CA2759015C (en) 2009-04-17 2017-06-20 James B. Mcclain Stents having controlled elution
SG178125A1 (en) 2009-08-03 2012-03-29 Univ Miami Method for in vivo expansion of t regulatory cells
JP2013509444A (ja) 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
CA2789622C (en) * 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
MX342590B (es) 2010-04-27 2016-10-05 Roche Glycart Ag Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
CN102234288B (zh) * 2010-05-06 2014-07-02 上海医药工业研究院 唑他莫司的制备方法
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
PT2675451E (pt) 2011-02-18 2015-10-16 Incyte Corp Terapia de combinação com inibidores mtor/jak
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
AU2012322085B2 (en) 2011-10-14 2017-05-04 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor Xia inhibitors
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
ES2668318T3 (es) 2012-10-12 2018-05-17 Bristol-Myers Squibb Company Formas cristalinas de inhibidor del factor XIa
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CA2863243A1 (en) * 2012-11-30 2014-06-05 Hangzhou Zylox Pharma Co., Ltd. Rafamycin analogs and methods for making same
KR20150136047A (ko) 2013-01-09 2015-12-04 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
JP6330024B2 (ja) 2013-03-12 2018-05-23 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP3068435A1 (en) 2013-11-13 2016-09-21 Novartis AG Mtor inhibitors for enhancing the immune response
CN116478927A (zh) 2013-12-19 2023-07-25 诺华股份有限公司 人间皮素嵌合抗原受体及其用途
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
US10428331B2 (en) 2014-01-16 2019-10-01 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
JP6464176B2 (ja) 2014-01-31 2019-02-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2760821T3 (ko) 2014-01-31 2018-03-10
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP3119425B1 (en) 2014-03-15 2020-09-23 Novartis AG Regulatable chimeric antigen receptor
AU2015237200A1 (en) 2014-03-27 2016-10-06 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
DK3129470T3 (da) 2014-04-07 2021-07-05 Novartis Ag Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
MX2016015569A (es) 2014-06-02 2017-04-25 Children´S Medical Center Corp Metodos y composiciones para inmunomodulacion.
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
PL3194443T3 (pl) 2014-09-17 2022-01-31 Novartis Ag Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3297629A1 (en) 2015-05-20 2018-03-28 Novartis AG Pharmaceutical combination of everolimus with dactolisib
US11357851B2 (en) 2015-11-11 2022-06-14 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
MX2019006090A (es) 2016-11-23 2019-08-21 Novartis Ag Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos.
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CA3107352A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
JP2022510573A (ja) 2018-07-23 2022-01-27 エンクリアー セラピーズ， インク． 神経障害の治療方法
WO2020210634A1 (en) 2019-04-11 2020-10-15 Enclear Therapies, Inc. Methods of amelioration of cerebrospinal fluid and devices and systems therefor
JP2023550544A (ja) 2020-11-03 2023-12-01 アールディスカバリー エルエルシー がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法
WO2023288046A1 (en) 2021-07-15 2023-01-19 President And Fellows Of Harvard College Compositions and methods relating to cells with adhered particles
CN116082362B (zh) * 2023-01-04 2024-05-10 山东大学 一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4105761B2 (ja) * 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
WO1998009970A2 (en) * 1996-09-09 1998-03-12 American Home Products Corporation Alkylated rapamycin derivatives
AU4246197A (en) * 1996-09-09 1998-03-26 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries

Also Published As

Publication number Publication date
JP2001517671A (ja) 2001-10-09
SI1015459T1 (en) 2005-10-31
EP1015459B1 (en) 2005-06-08
PL191212B1 (pl) 2006-03-31
BG64955B1 (bg) 2006-10-31
DE69830502T2 (de) 2006-05-11
KR100803639B1 (ko) 2008-02-19
TR200000778T2 (tr) 2000-07-21
AU745576B2 (en) 2002-03-21
EP1015459B9 (en) 2005-10-12
NO20001438D0 (no) 2000-03-20
CZ299365B6 (cs) 2008-07-02
ATE297398T1 (de) 2005-06-15
EP1015459A1 (en) 2000-07-05
WO1999015530A1 (en) 1999-04-01
CA2303934A1 (en) 1999-04-01
PL339455A1 (en) 2000-12-18
TW557297B (en) 2003-10-11
CA2303934C (en) 2010-01-26
DE69830502D1 (de) 2005-07-14
KR100700319B1 (ko) 2007-03-29
BR9812305A (pt) 2000-09-05
CO5070656A1 (es) 2001-08-28
KR20070086925A (ko) 2007-08-27
IL134607A0 (en) 2001-04-30
IL134607A (en) 2006-04-10
BG104316A (en) 2000-12-29
HU228368B1 (en) 2013-03-28
CN1271361A (zh) 2000-10-25
SK285408B6 (sk) 2007-01-04
CN1161360C (zh) 2004-08-11
NZ514778A (en) 2005-01-28
ES2244087T3 (es) 2005-12-01
SK4172000A3 (en) 2000-08-14
CZ20001014A3 (cs) 2000-07-12
NO325813B1 (no) 2008-07-21
NO20001438L (no) 2000-05-26
NZ502896A (en) 2001-12-21
PT1015459E (pt) 2005-09-30
DK1015459T3 (da) 2005-10-10
JP3790424B2 (ja) 2006-06-28
KR100833812B1 (ko) 2008-05-30
AU9581998A (en) 1999-04-12
AR015940A1 (es) 2001-05-30
KR20010024298A (ko) 2001-03-26
HK1030771A1 (en) 2001-05-18
KR20060071092A (ko) 2006-06-26
HUP0004556A2 (hu) 2001-10-28
HUP0004556A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
IL134607A0 (en) Tetrazole-containing rapamycin analogs with shortened half-lives
GB9720997D0 (en) Shock absorber
GB2345698B (en) Phthalocyanine analogs
DE59814003D1 (en) Thienopyrimidine
GB2328999B (en) Shock absorber
GB9809594D0 (en) Shock absorber
GB2325719B (en) Shock absorbing support
TW396962U (en) Mechanical pencil
TW389171U (en) Mechanical pencil
PL336307A1 (en) Crambescidin compounds
TW356768U (en) Double-chuck type mechanical pencil
GB9811463D0 (en) A body support
GB9719216D0 (en) Pen
GB9706700D0 (en) Absorber
TW322017U (en) Improved motocycle shock absorber
CA79779S (en) Banc
CA81692S (en) Pen
TW352699U (en) Improved structure for shock absorber
TW371922U (en) Pens
PL106250U1 (en) Derailer
TW322846U (en) Different-axis non-sharpening pencil
PL319446A1 (en) External stabiliser
GB9723837D0 (en) Bicycle stabiliser
GB9719305D0 (en) Pencil extension
GB9710441D0 (en) Pencils